pentapeptide raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2025-09-01. Anything still debated is marked as such rather than presented as settled.
At the molecular level, ipamorelin acts as an agonist at the growth hormone secretagogue receptor, also called the ghrelin receptor or GHS-R1a. Binding to this receptor on pituitary somatotroph cells triggers a signaling cascade that leads to growth hormone release. The effect is mediated through phospholipase C and calcium mobilization rather than through the cyclic AMP pathway used by growth hormone releasing hormone. The two pathways are complementary, and combined stimulation produces a larger response than either alone.
Compared with other secretagogues such as GHRP-2, GHRP-6, and hexarelin, ipamorelin is described as more selective. Published animal work reports little or no increase in adrenocorticotropic hormone, cortisol, or prolactin at doses that release growth hormone. This selectivity is the property most often cited in the research literature. Whether the same profile holds across species and dosing schedules remains an open question, since human data are limited and come largely from small studies.
Compared with older secretagogues such as hexarelin or GHRP-6, ipamorelin shows weaker stimulation of cortisol, prolactin, and appetite in the animal models used for early characterization. Whether that selectivity is preserved across longer human exposures remains an open question, because published clinical data are limited in size and duration. Reported effects on food intake are generally described as modest. The compound is therefore treated in the literature as a relatively selective research tool rather than a fully characterized therapeutic agent.
Ipamorelin is a synthetic pentapeptide that belongs to the growth hormone secretagogue class of compounds. Researchers at a pharmaceutical company first described it in the 1990s while screening small peptides for growth hormone releasing activity. Its chain contains five amino acid residues, two of which are non-natural building blocks, including 2-aminoisobutyric acid and a naphthylalanine derivative. The molecule was designed to act at the ghrelin receptor while avoiding several effects observed with earlier secretagogues.
At the cellular level, ipamorelin binds the growth hormone secretagogue receptor, also called the ghrelin receptor. Activation of this receptor on pituitary somatotroph cells triggers a signaling cascade that leads to release of growth hormone into circulation. Because release follows a pulsatile pattern, studies often report peak concentration and total area under the curve rather than a single time point. Selectivity for this receptor is the property most frequently discussed in comparative work.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic pentapeptide | Growth hormone secretagogue family |
| Molecular mass | Approximately 711.9 Da | Free base, calculated value |
| Receptor target | GHS-R1a, the ghrelin receptor | Agonist activity reported |
| Sequence | Aib-His-D-2-Nal-D-Phe-Lys-NH2 | C-terminal amide |
| Reported selectivity | Little change in ACTH, cortisol, prolactin | Based mainly on animal data |
Selectivity is the property most often attached to this peptide. Published animal and early human studies record increases in growth hormone release after administration, with adrenocorticotropic hormone and cortisol responses remaining small by comparison. Effects on appetite-related pathways also appear weaker than those reported for several earlier secretagogues. Reviews that compare members of the growth hormone secretagogue family cite these findings frequently, though the receptor-level explanation for the selectivity continues to be debated rather than settled.
Ipamorelin is a synthetic pentapeptide classified as a growth hormone secretagogue. Its sequence, Aib-His-D-2-Nal-D-Phe-Lys-NH2, combines three non-proteinogenic residues with a C-terminal amide. The N-terminal aminoisobutyric acid unit and the two aromatic D-amino acids distinguish it from peptides assembled only from standard L-amino acids. Its formula is C38H49N9O5, corresponding to an average mass near 711.9 Da. At neutral pH the molecule carries a net positive charge, a property that shapes its behaviour in chromatographic and electrophoretic systems.
Identity and purity are assessed by complementary methods rather than a single test. Reversed-phase high-performance liquid chromatography separates the peptide from related impurities and reports a percentage purity. Mass spectrometry, most often with electrospray ionization, confirms the expected molecular mass and detects sequence-related variants. Amino acid analysis can verify composition, while water content and residual counterion measurements support the mass balance of a batch. Stability studies under accelerated conditions are used to estimate shelf life, though such estimates carry uncertainty for long-term storage.
Material supplied for research use is normally a white to off-white lyophilized powder. The solid is hygroscopic and is handled in a low-humidity environment to limit water uptake. Bulk quantities are frequently shipped in sealed vials under inert gas. Once reconstituted in water or a neutral buffer, the solution is less stable than the dry powder and is usually divided into single-use aliquots.
Long-term storage of the dry powder is typically at minus twenty degrees Celsius or lower, protected from light and moisture. Solutions are commonly kept frozen and thawed only once, because repeated freeze-thaw cycles can promote aggregation and loss of measurable peptide content. Buffers near neutral pH are preferred over strongly acidic or strongly basic conditions. Shipping at ambient temperature is acceptable for short periods when the powder remains sealed and desiccated.
=== Commensals === The word "commensalism" is derived from the word "commensal", meaning "eating at the same table" and all plants and animals are colonised by commensal bacteria. In humans and other animals, trillions of them live on the skin, the airways, the gut and other orifices. Referred to as "normal flora", or "commensals", these bacteria usually cause no harm but may occasionally invade other sites of the body and cause infection. Escherichia coli is a commensal in the human gut but can cause urinary tract infections. Similarly, streptococci, which are part of the normal flora of the human mouth, can cause heart disease.
At the other extreme, a very large molecule that cannot penetrate any the smaller pores can enter only the interparticle volume (~35% of the column volume) and elutes earlier when this volume of mobile phase has passed through the column. The underlying principle of SEC is that particles of different sizes elute (filter) through a stationary phase at different rates. This results in the separation of a solution of particles based on size. Provided that all the particles are loaded simultaneously or near-simultaneously, particles of the same size should elute together. However, as there are various measures of the size of a macromolecule (for instance, the radius of gyration and the hydrodynamic radius), a fundamental problem in the theory of SEC has been the choice of a proper molecular size parameter by which molecules of different kinds are separated. Experimentally, Benoit and co-workers found an excellent correlation between elution volume and a dynamically based molecular size, the hydrodynamic volume, for several different chain architecture and chemical compositions. The observed correlation based on the hydrodynamic volume became accepted as the basis of universal SEC calibration. Still, the use of the hydrodynamic volume, a size based on dynamical properties, in the interpretation of SEC data is not fully understood. This is because SEC is typically run under low flow rate conditions where hydrodynamic factor should have little effect on the separation.
Elena Molokhovets's classic Russian cookbook A Gift to Young Housewives gives the first known recipe for Govjadina po-strogonovski, s gorchitseju, "Beef à la Stroganov, with mustard", in its 1871 edition. The recipe involves beef cubes (not strips) prepared in a dry marinade of salt and allspice, and then sautéed in butter. The sauce is a simple roux mixed with prepared mustard and broth, and finished with a small amount of sour cream: no onions, no mushrooms and no alcohol. In 1891, the French chef Charles Brière, who was working in Saint Petersburg, submitted a recipe for beef Stroganoff to a competition sponsored by the French magazine L'Art culinaire. This led Larousse Gastronomique to assume that he was the inventor of this dish, but both the recipe and the name existed before then.
In 1977, Lilly acquired IVAC Corporation, which manufactures vital signs and intravenous fluid infusion monitoring systems. The same year, Lilly acquired Cardiac Pacemakers, Inc., a manufacturer of pacemakers for $127 million. In 1980, Lilly acquired Physio-Control, a pioneering company in defibrillation. Advance Cardiovascular Systems was acquired in 1984 for $85 million in stock. Lilly acquired Hybritech in 1986 for $350 million; it was sold to Beckman Coulter in 1995. In 1988, it acquired Devices for Vascular Intervention for $50 million, with the potential for up to another $150 million in contingent payments. Lilly acquired Pacific Biotech in 1990; it was sold to QuidelOrtho in 1995 for $3.95 million. In 1992, Lilly acquired Origin Medsystems, which was developing several devices for use in laparoscopy. Heart Rhythm Technologies was acquired in 1992. Fluoxetine (Prozac), introduced in 1988, quickly became the company's best-selling product for treatment of depression, but Lilly lost its US patent protection for the product in 2001. Prozac was one of the first therapies in its class to treat clinical depression by blocking the uptake of serotonin within the human brain. In 1989, a joint agrochemical venture between Elanco and Dow Chemical created DowElanco. In 1997, Lilly sold its 40% share in the company to Dow Chemical for $1.2 billion and the name was changed to Dow AgroSciences. In 1991, Vaughn Bryson became president and CEO and Wood became board chairman.
=== Discovery === In the 1950s, a working group at the University of Pittsburgh conducted research on bacteria of the genus Lactobacillus, which require biotin as a growth factor. It has previously been shown that biotin is no longer necessary for the growth of bacteria if certain fatty acids are present in the culture medium instead. When investigating the influence of biotin on fatty acid metabolism, the researchers initially concentrated on the species L. arabinosus, which according to current systematics is classified as L. plantarum is carried out. They cultivated the bacteria in a semi-synthetic culture medium, harvested the cells and extracted the "free" lipids with acetone and diethyl ether. This fraction makes up about 20% of the total lipids. To obtain the "bound" lipids, an acid hydrolysis was then carried out, in which fatty acids bound as esters were released and also extracted with diethyl ether. The fatty acids were methylated with diazomethane to the methyl esters and separated according to their boiling points using fractional distillation. Based on the distillation curve, the presence of esters of C16, C18 and C19 fatty acids was expected. The fatty acid obtained from the C19 fraction showed a melting point at 28-29 °C after purification by recrystallization. The compound was investigated using numerous physical and chemical methods and its molecular formula was determined as C19H36O2. In 1950, this was only the second fatty acid with 19 carbon atoms to be isolated from microorganisms.
Sources: en.wikipedia.org
== Treatment == Treatment for diabulimia has two goals: stabilizing diabetes by increasing insulin intake and addressing the underlying eating disorder. The standard approach for the treatment of two complex conditions involves a multidisciplinary team of professionals. This team may include an endocrinologist, a psychiatrist, a psychologist, and a dietician. There are several treatment centers in the United States that have programs specifically designed for the co-morbidity of diabetes and eating disorders. There is one non-profit in the U.S. devoted to the education, support, and advocacy for people with diabetes and eating disorders. DBH runs a 24 hour toll-free crisis hotline +1.425.985.364 open 365 days a year.
Because this reaction is metal-free and proceeds with fast kinetics (k2 as fast as 60 1/Ms, faster than both the CuAAC or the SPAAC) SPANC can be used for live cell labeling. Moreover, substitution on both the carbon and nitrogen atoms of the nitrone dipole, and acyclic and endocyclic nitrones are all tolerated. This large allowance provides a lot of flexibility for nitrone handle or probe incorporation. However, the isoxazoline product is not as stable as the triazole product of the CuAAC and the SpAAC, and can undergo rearrangements at biological conditions. Regardless, this reaction is still very useful as it has notably fast reaction kinetics. The applications of this reaction include labeling proteins containing serine as the first residue: the serine is oxidized to aldehyde with NaIO4 and then converted to nitrone with p-methoxybenzenethiol, N-methylhydroxylamine and p-ansidine, and finally is incubated with cyclooctyne to give a click product. The SPANC also allows for multiplex labeling.
The political manifesto of the FLQ condemned English-Canadian imperialism in French Quebec and called for an independent, socialist Quebec. The Canadian government's response included the suspension of civil liberties in Quebec and compelled the FLQ leaders' flight to Cuba. Uruguay faced Marxist–Leninist revolution from the Tupamaros movement from the 1960s to the 1970s.
== Structure == AMH is a dimeric glycoprotein with a molar mass of 140 kDa. The molecule consists of two identical subunits linked by sulfide bridges, and characterized by the N-terminal dimer (pro-region) and C-terminal dimer. AMH binds to its Type 2 receptor AMHR2, which phosphorylates a type I receptor under the TGF beta signaling pathway.
== Prevalence == Approximately two-thirds of both INDs and new drug applications (NDAs) are small-molecule drugs. The rest is biopharmaceuticals. About half of the INDs fail in preclinical and clinical phases of drug development.
Sources: en.wikipedia.org
Ipamorelin is a synthetic pentapeptide that stimulates growth hormone release by activating the ghrelin receptor. It is handled as a research tool rather than as a licensed therapeutic product. Its short chain length makes it comparatively simple to synthesize and analyze.
Both bind the same receptor, but ghrelin is a 28-amino-acid hormone with roles in appetite and energy balance. Ipamorelin is a much smaller synthetic peptide selected for growth hormone release with limited effect on appetite signaling in animal models. The full overlap between their effects is not completely mapped.
Most published data come from animal studies and a small number of human trials. Findings on growth hormone release are reasonably consistent, while long-term effects and direct comparisons with other secretagogues remain incompletely studied. Open questions include duration of action across different populations.
It is a synthetic pentapeptide in the growth hormone secretagogue family. The chain contains five residues, two of which are non-natural amino acids.